Medical Device Licence Changes After Manufacturer/Company Changes: CDSCO Guide

Medical device licences in India are tightly linked to the legal identity and details of the manufacturer or authorised entity. Under the Medical Devices Rules (MDR), 2017, administered by the Central Drugs Standard Control Organisation (CDSCO), any change in the manufacturer’s name, address, constitution, or related company structure triggers specific regulatory obligations. These rules ensure continuity of accountability, quality oversight, and public health protection. This guide outlines the key requirements based on MDR 2017 provisions, including Rule 3(j), Rule 27, Rule 39, the Sixth Schedule, and related CDSCO clarifications.

Understanding “Change in Constitution” under MDR 2017

Rule 3(j) of the Medical Devices Rules, 2017, defines “change in the constitution of a licensee” clearly:

• For a firm: a shift from proprietorship to partnership (including Limited Liability Partnership) or vice versa.
• For a company: conversion from private to public company (or vice versa); any change in the ownership of shares of more than fifty per cent of the voting capital; or, in the case of a body corporate without share capital, any change in its membership. Where a managing agent is itself a subsidiary of another body corporate, a change in the constitution of that other body corporate is also included.

Simple changes in directors, or shareholding adjustments that do not exceed the 50% voting capital threshold, generally do not constitute a change in constitution. However, conversions such as partnership to LLP, firm to company, or private limited to public limited are treated as changes in constitution and require a fresh licence application.

Consequences of Change in Constitution

When a change in constitution occurs after grant of a manufacturing licence (under Rule 20 or Rule 25) or an import licence (under Rule 36):

• The licensee must inform the relevant Licensing Authority (State Licensing Authority or Central Licensing Authority, as applicable) in writing within 45 days (manufacturing) or as specified for import cases.
• A fresh application for grant of licence must be submitted within 180 days from the date of the change.
• The existing licence remains deemed valid until a fresh licence is issued or the application is rejected.
• If the application is rejected, an appeal may be filed with the Central or State Government within 60 days.

For import licences, the authorised agent must also inform the Central Licensing Authority of changes in the constitution of the overseas manufacturer or the authorised agent within the stipulated timelines (commonly referenced as 30–45 days in CDSCO FAQs). Fresh application in Form MD-14 is required, leading to a new Form MD-15 licence.

These timelines and the “deemed valid” provision prevent disruption of ongoing supply while ensuring the new legal entity is properly licensed and accountable.

Name or Address Changes Without Change in Constitution

Not every company change requires a completely fresh licence. The Sixth Schedule of MDR 2017 classifies certain updates as major or minor post-approval changes (PACs).

Major changes requiring prior approval from the Licensing Authority include:

• Change in the name or address of the domestic manufacturer or its manufacturing site.
• Change in the name or address of the overseas manufacturer or its manufacturing site (import cases).
• Change in the name or address of the authorised agent (import cases).

These are distinct from constitution changes. CDSCO FAQs confirm that a change in the actual manufacturing site name (without change in constitution or location) does not require a fresh licence; instead, approval is obtained through the Post Approval Change process on the Online System for Medical Devices.

For minor administrative updates (for example, certain address formatting changes without physical relocation or ownership shift), notification within 30 days may suffice, depending on classification. Change in registered office or correspondence address can often be handled by requesting updates through the CDSCO IT cell with supporting documents, without a full fresh application in some cases.

Procedure for Handling These Changes

1. Assess the nature of the change – Determine whether it qualifies as a change in constitution (Rule 3(j)), a major PAC under the Sixth Schedule, or a minor update.
2. Notify within timelines – Submit written intimation to the appropriate Licensing Authority within the prescribed period (45 days for most manufacturing constitution changes; shorter periods apply in certain import scenarios).
3. Prepare and submit application – For constitution changes, file a fresh application under the relevant rule (Rule 20/21 for manufacturing, Rule 34 for import) with updated constitution documents, plant master file (if applicable), device master file details, fees as per the Second Schedule, and supporting evidence (incorporation certificates, board resolutions, share transfer documents, etc.).
4. Post-approval change route – For name/address updates without constitution change, use the dedicated PAC module on the CDSCO medical devices portal. Provide revised labelling samples if required, updated Free Sale Certificate or other regulatory certificates where relevant, and an undertaking that quality, safety, and performance remain unaffected.
5. Maintain continuity – Continue operations under the existing licence during the transition period as permitted by the Rules. Update labelling, packaging, and marketing materials only after approval to avoid non-compliance.
6. Record-keeping and retention – All changes must be documented. At the time of licence retention (every five years), declarations confirming that all changes were properly notified are required.

Failure to comply can result in licence suspension, cancellation, or enforcement action under the Drugs and Cosmetics Act, 1940, and MDR 2017.

Practical Considerations for Manufacturers and Importers

Company restructurings, mergers, acquisitions, name rebranding, or relocation of offices/sites are common in the medical device sector. Early regulatory planning is essential. Documents such as updated Certificates of Incorporation, Memorandum and Articles of Association, Power of Attorney (for imports), and revised Quality Management System declarations must be ready. For overseas manufacturers, coordination with the Indian authorised agent is critical because the agent holds the import licence and bears notification responsibilities.

CDSCO has issued multiple FAQs and addenda clarifying that site-name changes without constitution or location change follow the PAC route, while true ownership or legal-form shifts demand a fresh licence. Always refer to the latest versions of the Rules, Sixth Schedule, and portal guidance, as procedural refinements continue through public notices.

Why Choose MDR Consultants

Navigating manufacturer or company changes under CDSCO and MDR 2017 involves precise classification of the change, strict adherence to timelines, correct form selection (MD-3/MD-5/MD-9 for manufacturing, MD-14/MD-15 for import), accurate document compilation, and seamless portal submissions. Errors in assessing whether a change is a constitution shift versus a simple PAC, or missing the 45/180-day windows, can lead to operational interruptions or regulatory non-compliance.

MDR Consultants specialise exclusively in medical device regulatory affairs under the Indian framework. Their team provides end-to-end support: change classification assessment, preparation of constitution documents and PAC dossiers, coordination with State and Central Licensing Authorities, portal filing, query response management, and post-approval labelling updates. By leveraging deep familiarity with MDR 2017 provisions, Sixth Schedule requirements, and current CDSCO practices, MDR Consultants help manufacturers and importers complete transitions efficiently, maintain licence continuity, and minimise business disruption. Choosing experienced regulatory partners ensures that company evolution does not compromise compliance or market access.

In summary, manufacturer and company changes are manageable under a clear regulatory pathway set out in the Medical Devices Rules, 2017. Timely notification, correct application type, and complete documentation keep licences valid and operations uninterrupted. Stakeholders should treat every structural or identity change as a regulatory event requiring proactive engagement with CDSCO processes.

Last Updated : 27 Aug 2026